IL159034A0 - A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin - Google Patents

A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin

Info

Publication number
IL159034A0
IL159034A0 IL15903402A IL15903402A IL159034A0 IL 159034 A0 IL159034 A0 IL 159034A0 IL 15903402 A IL15903402 A IL 15903402A IL 15903402 A IL15903402 A IL 15903402A IL 159034 A0 IL159034 A0 IL 159034A0
Authority
IL
Israel
Prior art keywords
ethoxy
phenyl
propanoic acid
insulin
tert
Prior art date
Application number
IL15903402A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL159034A0 publication Critical patent/IL159034A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15903402A 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin IL159034A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin

Publications (1)

Publication Number Publication Date
IL159034A0 true IL159034A0 (en) 2004-05-12

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15903402A IL159034A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin

Country Status (22)

Country Link
US (1) US20040147600A1 (cs)
EP (1) EP1401485A1 (cs)
JP (1) JP2004532873A (cs)
KR (1) KR20040072027A (cs)
CN (1) CN1535155A (cs)
BR (1) BR0210129A (cs)
CA (1) CA2448637A1 (cs)
CO (1) CO5540383A2 (cs)
CZ (1) CZ20033233A3 (cs)
EE (1) EE200300577A (cs)
HU (1) HUP0400964A3 (cs)
IL (1) IL159034A0 (cs)
IS (1) IS7056A (cs)
MX (1) MXPA03011012A (cs)
NO (1) NO20035236D0 (cs)
NZ (1) NZ529812A (cs)
PL (1) PL367704A1 (cs)
RU (1) RU2003136156A (cs)
SE (1) SE0101981D0 (cs)
SK (1) SK14712003A3 (cs)
WO (1) WO2002096453A1 (cs)
ZA (1) ZA200309261B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272926T3 (es) * 2003-11-28 2007-05-01 Merck Sante Tratamiento de hiperuricemia.
TW200640453A (en) * 2005-01-28 2006-12-01 Lilly Co Eli Formulations and dosing regimen for PPAR-α modulators
US20110165198A1 (en) * 2008-05-19 2011-07-07 Delphine Tissot-Favre Method for reducing lipid absorption by an animal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
ES2218338T3 (es) * 2000-04-13 2004-11-16 Pfizer Products Inc. Efecto sinergico de gliburida y milrinona.

Also Published As

Publication number Publication date
MXPA03011012A (es) 2004-02-27
SK14712003A3 (sk) 2004-08-03
US20040147600A1 (en) 2004-07-29
IS7056A (is) 2003-11-28
CO5540383A2 (es) 2005-07-29
CZ20033233A3 (cs) 2004-12-15
EP1401485A1 (en) 2004-03-31
NZ529812A (en) 2006-03-31
WO2002096453A1 (en) 2002-12-05
JP2004532873A (ja) 2004-10-28
PL367704A1 (en) 2005-03-07
EE200300577A (et) 2004-02-16
NO20035236D0 (no) 2003-11-25
CN1535155A (zh) 2004-10-06
CA2448637A1 (en) 2002-12-05
KR20040072027A (ko) 2004-08-16
BR0210129A (pt) 2004-06-08
RU2003136156A (ru) 2005-05-20
ZA200309261B (en) 2005-02-28
HUP0400964A2 (hu) 2004-08-30
HUP0400964A3 (en) 2007-11-28
SE0101981D0 (sv) 2001-06-01

Similar Documents

Publication Publication Date Title
LU92025I2 (fr) Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
PL1660482T3 (pl) Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku
EE200200278A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
DK1658056T3 (da) Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf
JP2006068522A (ja) おもちゃ組立ブロック
PL1667964T3 (pl) Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
IL159034A0 (en) A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin
PL377735A1 (pl) Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
IL159035A0 (en) A pharmaceutical combination comprising either (s) -2-ethoxy-3- [4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3- {4- [2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}- (s) -2-ethoxy propanoic acid and a sulfonylurea
HUP0400946A3 (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a biguanide drug
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
USD514327S1 (en) Disposable toothbrush
USD470527S1 (en) Camera base
MXPA05013716A (es) Procedimiento para la preparacion de acido 2-([2-(4 -hidroxifenil) etil]tio)-3 -[4-(2-(2- [metilsulfonil) oxi]fenoxi) etil)fenil] -propanoico racemico.
IL162405A (en) Process for preparing 2-(substituted phenyl)-2-hydroxyethyl carbamates and intermediates thereof
JPH11164721A (ja) 収納ケースの仕切り構造
JP2004152459A (ja) ディスクカートリッジ
JP2004345658A (ja) 包装箱
JPH0716706U (ja) コンパクト容器
AU2001277736A1 (en) 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-n-(1-(2-( -t-butyl-1,3,4-oxadiazolyl)carbonyl)-2-(r,s)-methylpropyl) acetamide hydrochloride